Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
$8.39
-$1.22(-11.32%)
At close: 4:00 PM EST
$8.39
-$1.22(-11.32%)
Day’s Range― - ―
52-Week Range$5.80 - $11.97
Previous CloseN/A
Volume4.15M
Average Volume (3M)3.89M
Market Cap
$1.32B
Enterprise Value$1.38B
Total Cash (Recent Filing)$735.08M
Total Debt (Recent Filing)$248.81M
Price to Earnings (P/E)2.5
Beta1.78
Next Earnings
May 13, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding162,935,940
10 Day Avg. Volume3,226,433
30 Day Avg. Volume3,890,779
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda2.79
Forecast
1Y Price Target
$12.67Price Target Upside51.01% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$396.19M
Bulls Say, Bears Say
Bulls Say
Cost ReductionsSustained and planned reductions in operating expenses improve the company's cash runway and financial stability, lowering the need for dilutive funding.
Licensing ValidationPfizer's license for Matrix-M provides an upfront payment plus milestone and tiered royalty potential, validating the adjuvant and creating a clear revenue pathway without full commercialization obligations.
Non-dilutive FinancingAccess to non-dilutive credit facilities supports progress toward non-GAAP profitability and reduces pressure for equity dilution while funding ongoing development.
Bears Say
Clinical Development TimingUncertainty about how quickly Matrix-M collaborations advance to clinical trials limits near-term visibility into milestone-driven revenue.
COVID Market Demand UncertaintyUnclear future demand for COVID vaccines and headline risk around competitors weaken the expected market size and revenue prospects tied to COVID-related products.
Reliance On Late-stage MilestonesMost financial upside depends on late-stage development and commercialization milestones, making valuation sensitive to timing and to potential clinical or regulatory setbacks.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.80 and its highest was $11.97 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.32B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is May 13, 2026 which is in 28 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Feb 26, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.595.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.23.
How many shares outstanding does Novavax have?
Novavax has 162,935,940 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $0.11 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went up 17.419%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.67 (51.01% Upside)
$12.67 (51.01% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-546.21%
Trailing 12-Months
Asset Growth
-26.20%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress: robust revenue growth (driven partly by noncash APA resolution), profitability in both Q4 and full‑year 2025, strong cash and credit resources with a runway into 2028, meaningful cost reductions, and accelerating partnership momentum (notably Pfizer and Sanofi) that together present a clear path to lower run‑rate costs and potential future milestone and royalty upside. Key risks highlighted include reliance on partner execution for meaningful future revenue, certain milestone timing uncertainties (tech transfer and Phase III milestones with Sanofi), front‑loaded partner‑related spending in 2026, and broader regulatory uncertainties that could affect product uptake. Overall, the positives (growth, profitability, cash runway, partnerships, and disciplined cost cuts) substantially outweigh the listed risks, though future value remains contingent on partner success and regulatory developments.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$12.67
▲(51.01% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Ownership Overview
0.51% Insiders
12.88% Mutual Funds
0.02% Other Institutional Investors
68.00% Public Companies and Individual Investors